Organon & Co. OGN
Organon & Co. ("Organon," the "Company," "we," "our," or "us") is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women's health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories. We sell these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers such as health maintenance organizations, pharmacy benefit managers and other institutions. We operate six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom ("UK"). Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B | $6.53B | $7.78B | — |
| Cost of revenue | $2.90B | $2.69B | $2.52B | $2.29B | $2.38B | $2.12B | $2.27B | — |
| Gross profit | $3.31B | $3.71B | $3.75B | $3.88B | $3.92B | $4.41B | $5.50B | — |
| R&D | — | — | — | — | $443.0M | $210.0M | $220.0M | — |
| SG&A | $1.72B | $1.76B | $1.89B | $1.70B | $1.67B | $1.36B | $1.44B | — |
| Interest expense | $504.0M | $520.0M | $527.0M | $422.0M | $258.0M | $0 | $0 | — |
| Pre-tax income | $425.0M | $807.0M | $673.0M | $1.12B | $1.53B | $2.75B | $3.70B | — |
| Income tax | $238.0M | $57.0M | $350.0M | $205.0M | $178.0M | $496.0M | $390.0M | — |
| Net income | $187.0M | $864.0M | $1.02B | $917.0M | $1.35B | $2.16B | $3.22B | — |
| EPS, basic | 0.72 | 3.36 | 4.01 | 3.61 | 5.33 | 8.52 | 12.69 | — |
| EPS, diluted | 0.72 | 3.33 | 3.99 | 3.59 | 5.31 | 8.52 | 12.69 | — |
| Shares, diluted (wtd. avg.) | $260.8M | $259.2M | $256.3M | $255.2M | $254.2M | $253.5M | $253.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $574.0M | $675.0M | $693.0M | $706.0M | $737.0M | $12.0M | $0 | $0 |
| Receivables | $1.33B | $1.36B | $1.74B | $1.48B | $1.38B | $1.04B | — | — |
| Inventory | $1.41B | $1.32B | $1.31B | $1.00B | $915.0M | $913.0M | — | — |
| Total current assets | $4.35B | $4.35B | $4.51B | $3.93B | $3.76B | $3.57B | — | — |
| Property, plant and equipment | $1.30B | $1.17B | $1.18B | $1.02B | $973.0M | $984.0M | — | — |
| Goodwill | $4.15B | $4.68B | $4.60B | $4.60B | $4.60B | $4.60B | — | — |
| Other intangibles | $1.13B | $1.41B | $533.0M | $649.0M | $651.0M | $503.0M | — | — |
| Total assets | $12.87B | $13.10B | $12.06B | $10.96B | $10.68B | $10.11B | — | — |
| Accounts payable | $952.0M | $1.15B | $1.31B | $1.13B | $1.38B | $259.0M | — | — |
| Short-term debt | $16.0M | $20.0M | $9.0M | $8.0M | $9.0M | $0 | — | — |
| Total current liabilities | $2.39B | $2.72B | $2.92B | $2.51B | $2.60B | $2.67B | — | — |
| Long-term debt | $8.63B | $8.86B | $8.75B | $8.90B | $9.12B | $0 | — | — |
| Total liabilities | $12.12B | $12.63B | $12.13B | $11.85B | — | — | — | — |
| Retained earnings | $1.11B | $1.01B | $443.0M | -$331.0M | -$998.0M | $0 | — | — |
| Total equity | $752.0M | $472.0M | -$70.0M | -$892.0M | -$1.51B | $5.49B | $7.04B | $6.35B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $700.0M | $939.0M | $799.0M | $858.0M | $2.16B | $2.28B | $3.02B | — |
| Depreciation and amortisation | $156.0M | $132.0M | $120.0M | $96.0M | $92.0M | $56.0M | $49.0M | — |
| Stock-based compensation | $77.0M | $105.0M | $101.0M | $75.0M | $59.0M | $40.0M | $41.0M | — |
| Capital expenditure | $162.0M | $175.0M | $251.0M | $196.0M | $192.0M | $255.0M | $92.0M | — |
| Investing cash flow | -$390.0M | -$513.0M | -$260.0M | -$420.0M | -$481.0M | -$250.0M | -$88.0M | — |
| Financing cash flow | -$561.0M | -$368.0M | -$569.0M | -$433.0M | -$977.0M | -$2.02B | -$2.93B | — |
| Dividends paid | $88.0M | $297.0M | $294.0M | $290.0M | $145.0M | $0 | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-177411.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |